{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"137"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).","groups":[{"description":"Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-CP With Prior Imatinib Only"},{"description":"Adult participants PH+ CML-AP (Accelerated Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG001","title":"CML-AP With Prior Imatinib Only"},{"description":"Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG002","title":"CML-CP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Number of Participants With Major Cytogenetic Response (MCyR)","type":"PRIMARY","unitOfMeasure":"Participants"}